Summary
This webinar uses a fluoxetine bioequivalence study to demonstrate how data analysis bridges the gap between classical PK and pharmacogenomics. By linking PK variability in healthy volunteers to 34 significant variants across 10 genes, notably CYP2D6 and CYP2C19, the session explores how PK phenotypes can support prospective profile identification and more precise, personalized antidepressant therapy. The presenter is Carlos Diaz Tufinio.
Key learning objectives
- Understand how PK analysis can be integrated with pharmacogenomic data
- Identify genetic variants that contribute to variability in drug response
- Apply PK phenotype insights to support more personalized antidepressant therapy
This webinar is ideal for
Clinical Pharmacologists, Pharmacokineticists
Register now
